09.24.11 - XBiotech Hosts Clinical Investigators
XBiotech hosted its clinical investigators in vascular disease over the weekend at a conference at the Barton Springs Resort in Austin, Texas. The investigator groups are involved in the multi-center clinical program titled “Open Label Randomized Study of the Safety, Pharmacokinetics and Preliminary Efficacy of an Anti-Inflammatory Antibody (CV-18C3) in Reducing Restenosis in Patients Undergoing Percutaneous Femoro-Popliteal Revascularization”. At its conclusion, the study will have enrolled 80 patients to determine if the Company’s lead therapeutic antibody to treat vascular inflammation can reduce the severity of restenosis in patients with advanced vascular disease in the leg. The conference included principal investigators, sub-principal investigators, study coordinators and nurses from each of the hospitals where clinical trials are being conducted. The group included those specializing in vascular surgery and cardiology, with attendees coming from hospitals in California, Florida, Georgia, Ohio and Texas. The investigators converged early on Saturday, September 24 at the Resort’s conference facilities to share their experiences in the study so far, and to discuss study refinements and monitoring strategies as the patient recruitment process gets into full swing. The conference also provided a forum for XBiotech to share ongoing results from the Company’s other clinical trials with investigators and coordinators. The Company’s President, Mr. John Simard commented on the meeting, saying “it [the meeting] was a tremendous success. I was in awe by the group assembled. I am indeed at a loss of words to express how fortunate I feel to have such an extraordinary group of people involved in the study. This group is clearly dedicated to understanding the role of our therapeutic antibody in the support of revascularization treatments; and it was evident from our discussions that we share a remarkably common vision for the importance of treating vascular inflammation. We are trying to develop a truly revolutionary advance in cardiovascular medicine; to this end, we could not have a more inspired group of clinical investigators. We will be there to support them in any way we can.”
© 2012 XBiotech USA, Inc. | All Rights Reserved